Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.

Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmüller G, Baeuerle PA, Dreier T.

Int J Cancer. 2002 Jul 1;100(1):101-10.

2.

Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines.

Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, Steiger C, Peters M, Baeuerle PA, da Silva AJ.

Br J Cancer. 2005 Jan 31;92(2):342-9.

3.

Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

Richter CE, Cocco E, Bellone S, Bellone M, Casagrande F, Todeschini P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2010 Dec;20(9):1440-7.

4.

Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model.

Lutterbuese P, Brischwein K, Hofmeister R, Crommer S, Lorenczewski G, Petersen L, Lippold S, da Silva A, Locher M, Baeuerle PA, Schlereth B.

Cancer Immunol Immunother. 2007 Apr;56(4):459-68.

PMID:
16937114
5.

Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Mol Cancer Ther. 2010 Jan;9(1):57-66. doi: 10.1158/1535-7163.MCT-09-0675.

6.

Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells.

Xiang W, Wimberger P, Dreier T, Diebold J, Mayr D, Baeuerle PA, Kimmig R.

J Cancer Res Clin Oncol. 2003 Jun;129(6):341-8.

PMID:
12819960
7.

High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.

Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS.

Mol Immunol. 2006 Mar;43(8):1183-93.

PMID:
16102830
8.

The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas.

Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, Litvinov SV.

Br J Cancer. 1998 Aug;78(4):478-83.

9.

Preparation of human IgG and IgM monoclonal antibodies for MK-1/Ep-CAM by using human immunoglobulin gene-transferred mouse and gene cloning of their variable regions.

Kuroki M, Yamada H, Shibaguchi H, Hachimine K, Hirose Y, Kinugasa T, Ishida I, Kuroki M.

Anticancer Res. 2005 Nov-Dec;25(6A):3733-9.

10.

High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2010 Dec;203(6):582.e1-7. doi: 10.1016/j.ajog.2010.07.041.

11.

Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.

Huls G, Heijnen IA, Cuomo E, van der Linden J, Boel E, van de Winkel JG, Logtenberg T.

Cancer Res. 1999 Nov 15;59(22):5778-84.

12.

Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.

Fogler WE, Klinger MR, Abraham KG, Gottlinger HG, Riethmuller G, Daddona PE.

Cancer Res. 1988 Nov 15;48(22):6303-8.

14.

Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients.

Staib L, Birebent B, Somasundaram R, Purev E, Braumüller H, Leeser C, Küttner N, Li W, Zhu D, Diao J, Wunner W, Speicher D, Beger HG, Song H, Herlyn D.

Int J Cancer. 2001 Apr 1;92(1):79-87.

15.

In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule.

Ammons WS, Bauer RJ, Horwitz AH, Chen ZJ, Bautista E, Ruan HH, Abramova M, Scott KR, Dedrick RL.

Neoplasia. 2003 Mar-Apr;5(2):146-54.

16.

The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells.

Abdullah N, Greenman J, Pimenidou A, Topping KP, Monson JR.

Cancer Immunol Immunother. 1999 Dec;48(9):517-24.

PMID:
10602889
17.

An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy.

McLaughlin PM, Kroesen BJ, Dokter WH, van der Molen H, de Groot M, Brinker MG, Kok K, Ruiters MH, Buys CH, de Leij LF.

Cancer Immunol Immunother. 1999 Sep;48(6):303-11.

PMID:
10473805
18.

EpCAM: A new therapeutic target for an old cancer antigen.

Armstrong A, Eck SL.

Cancer Biol Ther. 2003 Jul-Aug;2(4):320-6. Review.

PMID:
14508099
19.
20.

Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice.

Zaloudik J, Li W, Jacob L, Kieny MP, Somasundaram R, Acres B, Song H, Zhang T, Li J, Herlyn D.

Cancer Gene Ther. 2002 Apr;9(4):382-9.

Supplemental Content

Support Center